marketing the product in 1980 because of liver toxicity observed after approval of the NDA. SmithKline waived its opportunity for a hearing.

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of NDA 18–103, and all amendments and supplements thereto, is hereby withdrawn effective May 20, 1996.

Dated: May 6, 1996. Murray M. Lumpkin, Deputy Director, Center for Drug Evaluation and Research. [FR Doc. 96–12570 Filed 5–15–96; 8:45 am] BILLING CODE 4160–01–F

### **Health Care Financing Administration**

#### Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Health Care Financing Administration.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, is publishing the following summaries of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

1. Type of Information Collection *Request:* New Collection; *Title of* Information Collection: Evaluation of the Oregon Medicaid Reform Demonstration: Adult Interview, Child Interview, Pediatric Asthma Interview, Insulin-Dependent Diabetes Interview, Low Back Pain Interview, Medical Provider Questionnaire; Form No.: HCFA-R-192; Use: The survey instruments listed above are for use in the Evaluation of the Oregon Medicaid Reform Demonstration. The Adult and Child Interviews are designed to collect information related to health status, access to care, satisfaction with care and

past health insurance status for adult and child members of the Oregon Health Plan (OHP). The Pediatric Asthma Interview, Insulin-Dependent Diabetes Interview and Low Back Pain Interview collect information on quality of care, utilization of care, satisfaction with care and health status of OHP members with selected "tracer conditions." The Medical Provider Questionnaire is designed to collect information on how both participating and non-participating physicians view OHP; Frequency: Biennially, Other (one time); Affected Public: Not-for-profit institutions, individuals and households, business or other for-profit; Number of Respondents: 22,229; Total Annual Hours: 3,070.

2. Type of Information Collection Request: New Collection; Title of Information Collection: Evaluation of the Per-Episode Home Health Prospective Payment Demonstration; Form No.: HCFA-R-195; Use: This evaluation will collect primary data from samples of patients and from demonstration agencies to assess impacts of per-episode payment on access to care, quality of care, and the use of non-Medicare services; Frequency: Other (one time); Affected Public: Not-for-profit institutions, individuals and households, business or other for-profit; Number of Respondents: 19,191; Total Annual Hours: 1,901

3. Type of Information Collection *Request:* Extension of a currently approved collection; Title of Information Collection: Blood Bank Inspection Checklist and Report; Form No.: HCFA-282; Use: The blood bank inspection checklist instrument is used by the State agency to record data collected as part of the survey and certification process to determine compliance with the requirement for blood bank services under Clinical Laboratory Improvement Amendments; Frequency: Biennially; Affected Public: State, local, and tribal government, business or other for-profit, not-forprofit institutions, federal government; Number of Respondents: 2,500; Total Annual Hours: 1,250.

To obtain copies of the supporting statement for the proposed paperwork collections referenced above, access HCFA's WEB SITE ADDRESS at http:// www.ssa.gov/hcfa/hcfahp2.html, or to obtain the supporting statement and any related forms, E-mail your request, including your address and phone number, to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786–1326. Written comments and recommendations for the proposed information collections must be mailed within 60 days of this notice directly to the HCFA Paperwork Clearance Officer designated at the following address: HCFA, Office of Financial and Human Resources, Management Planning and Analysis Staff, Attention: John Burke, Room C2–26–17, 7500 Security Boulevard, Baltimore, Maryland 21244– 1850.

Dated: May 13, 1996.

#### Kathleen B. Larson,

Director, Management Planning and Analysis Staff, Office of Financial and Human Resources, Health Care Financing Administration.

[FR Doc. 96–12527 Filed 5–17–96; 8:45 am] BILLING CODE 4120–03–P

#### National Institutes of Health

## National Institute on Deafness and Other Communication Disorders; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, amended (5 United States Code Appendix 2), notice is hereby given of the following meeting:

*Name of Committee:* Communication Disorders Review Committee.

Date: June 5–7, 1996.

*Time:* 8 am–5:30 pm, June 5; 8 am–5:30 pm, June 6; 8 am–adjournment, June 7.

*Place:* Doubletree Hotel, 1750 Rockville Pike, Rockville MD 20852.

*Contact Person:* Craig A. Jordan, Ph.D., Scientific Review Administrator, NIDCD/ DEA/SRB, EPS Room 400C, 6120 Executive Boulevard, MSC 7180, Bethesda MD 20892– 7180, 301–496–8683.

Purpose/Agenda: To review and evaluate grant applications. The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, United States Code. The applications and/or proposals and the discussion could reveal confidential trade secrets or commercial property such as patentable material and personnal information concerning individuals associated with the applications and/or proposals, the disclosure of which could constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program No. 93.173 Biological Research Related to Deafness and Communication Disorders)

Dated: May 10, 1996.

#### Susan K. Feldman,

Committee Management Officer, NIH. [FR Doc. 96–12503 Filed 5–17–96; 8:45 am] BILLING CODE 4140–01–M

# National Cancer Institute; Notice of Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as